Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

String of Pearls: Lessons in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

At 21 weeks of follow-up, both intervention groups had significantly increased their number of steps and also demonstrated statistically significant improvement in fatigue as rated by the Patient-Reported Outcomes Measurement Information System seven-item questionnaire.3 Dr. Ormseth used this study to illustrate the potential role for increased exercise in addressing symptoms of fatigue in patients with rheumatoid arthritis.

Tofacitinib & Cardiovascular Disease

In the third case, a 70-year-old man with seropositive rheumatoid arthritis and a significant history of cardiovascular disease is described as having ongoing disease activity despite subcutaneous methotrexate at full dose. When considering additional treatment options, Dr. Ormseth noted that tofacitinib would be among the riskier choices for this patient.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This is based on the ORAL Surveillance study, in which patients aged 50 and older with moderate to severe RA, one or more cardiac risk factors and inadequate response to methotrexate were divided into one of three clinical arms: 5 mg of tofacitinib given twice daily plus methotrexate, 10 mg of tofacitinib given twice daily plus methotrexate (after the drug safety monitoring review, this dose was lowered to 5 mg given twice daily) or a tumor necrosis factor-α (TNF) inhibitor plus methotrexate.4

The study demonstrated that tofacitinib combined with methotrexate was not non-inferior to TNF inhibitors plus methotrexate. The number needed to harm for major adverse cardiac events over one year was 567 for 5 mg of tofacitinib twice daily and 319 for 10 mg of tofacitinib twice daily.4 Independent risk factors for major adverse cardiac events included current smoking, aspirin use, being 65 years or older and being male. In addition, the highest rates of major adverse cardiac events were seen in patients with coronary artery disease and in patients with a high risk of major adverse cardiac events based on traditional risk factors.5 Dr. Ormseth summarized these findings in the form of a clinical pearl that states how tofacitinib should generally be avoided in patients with cardiovascular disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

RA & Hepatitis B

The fourth case was of a 44-year-old woman with seropositive, erosive rheumatoid arthritis who has been treated with methotrexate and sulfasalazine but has not been able to tolerate increased doses of these medications and has high disease activity. On lab studies, she is found to have a history of hepatitis B infection.

Using the 2021 ACR guideline, Dr. Ormseth explained that prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients who are positive for hepatitis B core antibody and are planning on initiating rituximab.1 In addition, for patients with evidence of chronic hepatitis B infection (i.e., hepatitis B core antibody positive and hepatitis B surface antigen positive), prophylactic antiviral therapy is strongly recommended over frequent monitoring alone prior to starting biologic disease-modifying anti-rheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022Rheumatoid arthritisRheumatoid Arthritis (RA)

Related Articles

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    December 7, 2021

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    Old Drugs Can Learn New Tricks

    November 1, 2011

    Methotrexate and its mechanism of action

    Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

    September 19, 2017

    MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings came in a one-year…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences